HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Ernesto L Schiffrin Selected Research

Desoxycorticosterone (Deoxycorticosterone)

7/2013Reduced macrophage-dependent inflammation improves endothelin-1-induced vascular injury.
1/2012Immune modulation of resistance artery remodelling.
3/2010T lymphocytes: a role in hypertension?
4/2007Resistance artery remodeling in deoxycorticosterone acetate-salt hypertension is dependent on vascular inflammation: evidence from m-CSF-deficient mice.
2/2005Dual angiotensin-converting enzyme/neutral endopeptidase inhibition on cardiac and renal fibrosis and inflammation in DOCA-salt hypertensive rats.
4/2004ETA receptor mediates altered leukocyte-endothelial cell interaction and adhesion molecules expression in DOCA-salt rats.
10/2003ETA receptor blockade decreases vascular superoxide generation in DOCA-salt hypertension.
4/2003Role of endothelin-1 in hypertension.
2/2002Fibrosis, matrix metalloproteinases, and inflammation in the heart of DOCA-salt hypertensive rats: role of ET(A) receptors.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Ernesto L Schiffrin Research Topics

Disease

135Hypertension (High Blood Pressure)
05/2022 - 01/2002
52Inflammation (Inflammations)
01/2022 - 02/2002
33Vascular Remodeling
01/2022 - 01/2002
30Cardiovascular Diseases (Cardiovascular Disease)
01/2021 - 06/2002
21Fibrosis (Cirrhosis)
01/2021 - 02/2002
20Heart Failure
01/2021 - 01/2004
15Vascular System Injuries
01/2022 - 02/2003
14Chronic Renal Insufficiency
01/2022 - 06/2005
13Stroke (Strokes)
02/2012 - 01/2002
12Atherosclerosis
01/2021 - 10/2002
11Diabetes Mellitus
01/2021 - 05/2002
11Myocardial Infarction
01/2021 - 06/2005
11Hypertrophy
01/2014 - 02/2002
9Cardiomegaly (Heart Hypertrophy)
04/2016 - 10/2003
9Body Weight (Weight, Body)
05/2010 - 06/2005
8Insulin Resistance
04/2011 - 05/2002
7Metabolic Syndrome (Dysmetabolic Syndrome X)
01/2021 - 12/2004
7Vascular Diseases (Vascular Disease)
01/2018 - 10/2002
7Isolated Systolic Hypertension
01/2017 - 06/2005
7Albuminuria
07/2011 - 06/2005
5Obesity
01/2021 - 06/2003
5Coronary Artery Disease (Coronary Atherosclerosis)
11/2014 - 01/2004
4Cerebrovascular Disorders (Cerebrovascular Occlusion)
05/2010 - 05/2007
4Type 2 Diabetes Mellitus (MODY)
07/2008 - 03/2002
3Hyperaldosteronism (Conn Syndrome)
01/2016 - 02/2003
3Proteinuria
05/2010 - 02/2003
3Dyslipidemias (Dyslipidemia)
05/2010 - 06/2005
3Hypercholesterolemia
09/2009 - 08/2004
2Kidney Diseases (Kidney Disease)
10/2022 - 07/2011

Drug/Important Bio-Agent (IBA)

47Angiotensin IIIBA
01/2019 - 05/2002
28SaltsIBA
01/2021 - 01/2002
26AldosteroneIBA
01/2021 - 02/2002
24Endothelin-1 (Endothelin 1)IBA
01/2021 - 02/2002
20Endothelins (Endothelin)IBA
01/2020 - 02/2002
19Angiotensin Receptor AntagonistsIBA
01/2018 - 03/2002
16AngiotensinsIBA
01/2020 - 12/2002
15Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA
01/2018 - 10/2002
14Reactive Oxygen Species (Oxygen Radicals)IBA
01/2021 - 10/2002
13Antihypertensive Agents (Antihypertensives)IBA
03/2022 - 06/2002
11CollagenIBA
05/2016 - 02/2002
10CytokinesIBA
05/2022 - 05/2007
10NADPH Oxidases (NAD(P)H oxidase)IBA
01/2021 - 12/2002
9Peroxisome Proliferator-Activated Receptors (PPAR)IBA
01/2017 - 10/2003
9LipidsIBA
01/2016 - 03/2005
9Calcium Channel Blockers (Blockers, Calcium Channel)IBA
01/2016 - 06/2005
9Proteins (Proteins, Gene)FDA Link
01/2014 - 02/2002
9Desoxycorticosterone (Deoxycorticosterone)IBA
07/2013 - 02/2002
9Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)IBA
07/2011 - 06/2003
9PPAR gammaIBA
07/2008 - 05/2002
8Nitric Oxide (Nitrogen Monoxide)FDA Link
03/2011 - 10/2002
8PPAR alphaIBA
07/2008 - 12/2002
8Desoxycorticosterone Acetate (DOCA)FDA Link
04/2007 - 02/2002
7Messenger RNA (mRNA)IBA
01/2022 - 04/2003
7MineralocorticoidsIBA
01/2015 - 02/2002
71,4-dihydropyridine (dihydropyridine)IBA
07/2011 - 06/2005
7CholesterolIBA
09/2010 - 06/2005
7Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA
05/2010 - 06/2005
6Apolipoproteins E (ApoE)IBA
01/2021 - 02/2011
6Vasoconstrictor AgentsIBA
12/2019 - 10/2002
6Dietary SodiumIBA
02/2014 - 05/2007
6Acetates (Acetic Acid Esters)FDA Link
07/2013 - 02/2002
6ThiazidesIBA
05/2010 - 06/2005
5Peptides (Polypeptides)IBA
12/2019 - 03/2003
5Losartan (Cozaar)FDA LinkGeneric
04/2016 - 10/2002
5Mineralocorticoid Receptor AntagonistsIBA
01/2015 - 07/2003
5DiureticsIBA
01/2012 - 05/2007
5Insulin (Novolin)FDA Link
04/2011 - 04/2004
5AntioxidantsIBA
02/2011 - 01/2002
4Biomarkers (Surrogate Marker)IBA
01/2021 - 07/2008
4Glucose (Dextrose)FDA LinkGeneric
01/2019 - 06/2007
4Transcription Factors (Transcription Factor)IBA
01/2019 - 11/2005
4Neprilysin (Neutral Endopeptidase)IBA
01/2018 - 11/2003
4Matrix Metalloproteinases (MMPs)IBA
12/2017 - 02/2002
4Mineralocorticoid Receptors (Mineralocorticoid Receptor)IBA
05/2016 - 11/2005
4C-Reactive ProteinIBA
07/2011 - 12/2004
4Rosiglitazone (Avandia)FDA Link
02/2010 - 01/2003
4Superoxides (Superoxide)IBA
12/2009 - 10/2003
3MicroRNAs (MicroRNA)IBA
01/2022 - 01/2019
3ApolipoproteinsIBA
01/2021 - 10/2013
3ReninIBA
01/2020 - 06/2003
3Matrix Metalloproteinase 2 (Gelatinase A)IBA
12/2017 - 06/2002
3Fibronectins (Fibronectin)IBA
05/2016 - 02/2002
3Aspirin (Acetylsalicylic Acid)FDA LinkGeneric
05/2014 - 06/2005
3Macrophage Colony-Stimulating FactorIBA
07/2013 - 10/2005
3Type 2 Angiotensin ReceptorIBA
02/2012 - 05/2005
3Sodium Chloride Symporter Inhibitors (Diuretics, Thiazide)IBA
07/2011 - 05/2007
3Nitric Oxide Synthase (NO Synthase)IBA
12/2009 - 10/2002
3Follicle Stimulating Hormone (Follitropin)FDA Link
09/2009 - 10/2003
3ThiazolidinedionesIBA
07/2008 - 05/2002
3Valsartan (Vals)FDA Link
02/2008 - 10/2002
3NADP (NADPH)IBA
04/2007 - 10/2002
35- (dimethylamino)- N- (3,4- dimethyl- 5- isoxazolyl)- 1- naphthalenesulfonamideIBA
07/2003 - 02/2002
2Interleukin-10 (Interleukin 10)IBA
05/2022 - 06/2013
2Vascular Cell Adhesion Molecule-1 (Vascular Cell Adhesion Molecule 1)IBA
01/2021 - 11/2005
2dihydroethidiumIBA
01/2021 - 11/2016
2Interleukin-17 (Interleukin 17)IBA
01/2021 - 01/2012
2Drinking WaterIBA
05/2016 - 01/2002
2Oxygen (Dioxygen)IBA
04/2016 - 04/2006

Therapy/Procedure

28Therapeutics
01/2022 - 06/2002
3Denervation
12/2014 - 02/2013